Key facts
- This page summarizes Suzanne Ildstad's Form 4 filing for Talaris Therapeutics, Inc. (TRML).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Jun 2023, 18:58.
Suzanne Ildstad - 12 Jun 2023 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)
- Reporting relationship
- Director
- Issuer ticker
- TRML
- Reported as of
- 12 Jun 2023
- Net transaction value
- -$112,307
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2023, 18:58:15 UTC
- Prior SEC filing
- 09 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mary Kay Fenton, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Suzanne Ildstad filed Form 4 for Talaris Therapeutics, Inc. (TRML) on 14 Jun 2023.
Change
- Previous filing in this sequence was filed on 09 Jun 2023.
- Current net transaction value: -$112,307.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TALS
transaction
Common Stock
Sale
- Transaction value
- $43,725
- Shares
- -16,870
- Change %
- -0.44%
- Price
- $2.59
- Shares after
- 3,798,542
- Date
- 12 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
TALS
transaction
Common Stock
Sale
- Transaction value
- $36,338
- Shares
- -14,208
- Change %
- -0.37%
- Price
- $2.56
- Shares after
- 3,784,334
- Date
- 13 Jun 2023
- Ownership
- Direct
- Footnotes
- F2
TALS
transaction
Common Stock
Sale
- Transaction value
- $32,244
- Shares
- -12,942
- Change %
- -0.34%
- Price
- $2.49
- Shares after
- 3,771,392
- Date
- 14 Jun 2023
- Ownership
- Direct
- Footnotes
- F3
TALS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 654,205
- Date
- 12 Jun 2023
- Ownership
- See footnote
- Footnotes
- F4
TALS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 654,205
- Date
- 12 Jun 2023
- Ownership
- See footnote
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TALS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +20,500
- Change %
- Price
- $0.000000
- Shares after
- 20,500
- Date
- 13 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,500
- Exercise price
- $2.54
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 6 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.43 to $2.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
These shares are held in a trust for the benefit of the Reporting Person's son. The Reporting Person's son is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Footnote F5
These shares are held in a trust for the benefit of the Reporting Person's daughter. The Reporting Person's daughter is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Footnote F6
The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.